Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjectsSreeneeranj Kasichayanula, David W. Boulton, T. Li et al.|Diabetes Obesity and Metabolism|2010Cited by 90
Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozinSreeneeranj Kasichayanula, David W. Boulton, Xuejun Liu et al.|Diabetes Obesity and Metabolism|2012Cited by 67
Bioequivalence and Food effect of heat-stressed and non-heat-stressed Dapagliflozin TabletsDavid W. Boulton, Ravindra W. Tejwani, Kevin Volk et al.|Clinical Therapeutics|2015Cited by 0